根据冠状动脉钙化与BMI分配司美格鲁肽:将SELECT试验应用于MESA
在无糖尿病或临床心血管病的MESA参与者中,按冠状动脉钙化(CAC)评分模拟司美格鲁肽分配;CAC≥300较CAC=0的MACE风险高2.16倍,5年需治疗人数(NNT)在CAC=0与CAC≥300间差异大(MACE 653 vs 79),提示CAC测量可能提升减重剂量司美格鲁肽的价值。
要点
- CAC≥300者较CAC=0的MACE风险显著升高(HR 2.16,95%CI 1.57-2.99)。
- CAC≥300与CAC=0的5年NNT差异大:MACE 653 vs 79,HF 1094 vs 144。
- CAC测量可能改善有限医疗资源下减重剂量司美格鲁肽的分配。
核心结论
- 在无糖尿病或临床心血管病者中,CAC测量可能提升减重剂量司美格鲁肽治疗的价值,改善有限医疗资源的分配。
研究设计与样本
- 基于MESA中3129例无糖尿病或临床心血管病且符合司美格鲁肽BMI标准并接受非对比心脏CT钙化评分者的分析;采用Cox比例风险回归,并将SELECT试验(中位随访3.3年)的风险降低估计应用于观察发生率计算5年NNT。
诊断标准与关键数值
- CAC≥300 vs CAC=0:MACE的HR 2.16(95%CI 1.57-2.99),P<0.001。
- CAC≥300 vs CAC=0:心衰的HR 2.80(95%CI 1.81-4.35),P<0.001。
- CAC≥300 vs CAC=0:慢性肾病的HR 1.59(95%CI 1.15-2.22),P=0.006。
- CAC≥300 vs CAC=0:全因死亡的HR 1.35(95%CI 1.08-1.69),P=0.009。
- 5年NNT:CAC=0 vs CAC≥300,MACE 653 vs 79,心衰1094 vs 144,慢性肾病1044 vs 144,全因死亡408 vs 98。
临床应用与阅片要点
- 作者认为,CAC测量可能提升无糖尿病或临床心血管病者接受减重剂量司美格鲁肽治疗的价值,改善有限医疗资源的分配。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Implementation of semaglutide weight loss therapy has been challenging due to drug supply and cost, underscoring a need to identify those who derive the greatest absolute benefit.
OBJECTIVES: Allocation of semaglutide was modeled according to coronary artery calcium (CAC) among individuals without diabetes or established atherosclerotic cardiovascular disease (CVD).
METHODS: In this analysis, 3,129 participants in the MESA (Multi-Ethnic Study of Atherosclerosis) without diabetes or clinical CVD met body mass index criteria for semaglutide and underwent CAC scoring on noncontrast cardiac computed tomography. Cox proportional hazards regression assessed the association of CAC with major adverse cardiovascular events (MACE), heart failure (HF), chronic kidney disease (CKD), and all-cause mortality. Risk reduction estimates from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial (median follow-up: 3.3 years) were applied to observed incidence rates for semaglutide 5-year number-needed-to-treat calculations.
RESULTS: Mean age was 61.2 years, 54% were female, 62% were non-White, mean body mass index was 31.8 kg/m2, and 49% had CAC. Compared with CAC = 0, CAC ≥300 conferred a 2.2-fold higher risk for MACE (HR: 2.16 [95% CI: 1.57-2.99]; P < 0.001). Higher risks for HF (HR: 2.80 [95% CI: 1.81-4.35]; P < 0.001), CKD (HR: 1.59 [95% CI: 1.15-2.22]; P = 0.006), and all-cause mortality (HR: 1.35 [95% CI: 1.08-1.69]; P = 0.009) comparing CAC ≥300 vs CAC = 0 were also observed. There were large 5-year number-needed-to-treat differences between CAC = 0 and CAC ≥300 for MACE (653 vs 79), HF (1,094 vs 144), CKD (1,044 vs 144), and all-cause mortality (408 vs 98).
CONCLUSIONS: Measurement of CAC may enhance value of care with weight loss dose semaglutide in those without diabetes or clinical CVD, improving allocation of a limited health care resource.
引用
- Razavi AC, Cao Zhang AM, Dardari ZA, et al. Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA. JACC Cardiovasc Imaging. 2025. PMID: 39797878. doi:10.1016/j.jcmg.2024.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。